<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898338</url>
  </required_header>
  <id_info>
    <org_study_id>BACSARM</org_study_id>
    <secondary_id>2013-000586-37</secondary_id>
    <nct_id>NCT01898338</nct_id>
  </id_info>
  <brief_title>Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia</brief_title>
  <official_title>Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miquel Pujol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Network for Research in Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin
      alone in the treatment of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mortality associated to MRSA bacteremia remains higher than 30% of episodes despite the
      availability of new antibiotics. Objective: To demonstrate that the combination of daptomycin
      and fosfomycin is superior to daptomycin alone in the treatment of methicillin resistant
      Staphylococcus aureus (MRSA) bacteremia. Design: Randomized, open-label and multicenter
      study. Intervention: Patients with MRSA bacteremia will be randomized (1:1) in Group 1:
      daptomycin 10mg/Kg/24h intravenous (iv) and Group 2: daptomycin 10 mg/kg/24 iv plus
      fosfomycin and 2g/6h iv. Duration of therapy will be 10-14 days for uncomplicated bacteremia
      and up to 42 days for complicated bacteremia. Follow up: There will be a clinical and
      microbiological evaluation at baseline, during treatment and at week 6 after the end of
      therapy (test of cure visit, TOC). Complicated bacteremia was considered if: a) persistence
      of a positive blood culture at 72-96 h from the start of antibiotic, b) evidence of spread of
      infection (metastatic infection) c) infection involving a non-removable device in less than 4
      days. Sample size: Assuming 60% cure rate with daptomycin and a 20% difference in cure rates
      between both groups, we estimated that 103 patients will be needed for each group (α:0.05, ß:
      0.2). Main endpoint: clinical and microbiological response at the TOC visit. Treatment
      success was defined as the resolution of clinical signs and symptoms and negative blood
      culture. Treatment failure was defined if any of the following situations: a) lack of
      clinical response at 72 h or more after initiation of the study therapy b) persistent
      bacteremia (positive blood culture on day 7 after randomization), c) withdrawal of treatment
      due to adverse effects or for any other reason based on clinical judgment. d) relapse of MRSA
      bacteremia before the TOC visit e) death for any reason before the TOC visit. Secondary
      endpoints: evaluation in both groups of clinical and microbiological response at end of
      therapy (EOT visit); mortality at EOT and TOC visit; persistent MRSA bacteremia; recurrence
      of MRSA bacteremia (positive blood culture when previous ones were negative); emergence of
      daptomycin or fosfomycin resistance and severe adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapy response</measure>
    <time_frame>at week 6 after end of therapy (an average of 8 to 12 weeks from the beginnig of therapy)</time_frame>
    <description>Therapy response is considered if clinical and microbiological response is achieved at week 6 after end of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>participants will be followed an average of 8 to 12 weeks from the begining of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse effects</measure>
    <time_frame>participants will be followed an average of 8 to 12 weeks from the begining of therapy</time_frame>
    <description>whatever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of persistent bacteremia</measure>
    <time_frame>participants will be followed an average of 8 to 12 weeks from the begining of therapy</time_frame>
    <description>Defined as a positive blood culture on day 7 after starting the study therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteremia recurrence</measure>
    <time_frame>participants will be followed an average of 8 to 12 weeks from the begining of therapy</time_frame>
    <description>Defined as a positive blood culture to MRSA when previous ones were negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy response at end of therapy (EOT visit)</measure>
    <time_frame>at end of therapy</time_frame>
    <description>Success is considered if clinical resolution and negative blood culture at end of therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Staph Aureus Methicillin Resistant Bacteremia</condition>
  <arm_group>
    <arm_group_label>Fosfomycin and Daptomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daptomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daptomycin 10mg/kg/cada 24h iv during 14 or 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosfomycin 2gr/6h iv</intervention_name>
    <arm_group_label>Fosfomycin and Daptomycin</arm_group_label>
    <arm_group_label>Daptomycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin 10mg/kg/24h iv</intervention_name>
    <arm_group_label>Fosfomycin and Daptomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with at least 1 positive blood culture to MRSA within 72h up to randomization

          -  Adult patients, equal or older than 18 years old

          -  Signed informed consent

          -  Mandatory use of contraception methods for fertile women during the study period and
             for 6 months after stopping antibiotic therapy

        Exclusion Criteria:

          -  Polymicrobial bacteremia

          -  Pneumonia associated to the bacteremia

          -  Severe clinical status with expected survival of less than 24 hours

          -  Allergy to daptomycin or fosfomycin

          -  A positive pregnancy test at the time of inclusion

          -  Any clinical condition that requires additional antibiotic therapy with
             microbiological activity against MRSA

          -  Patient already included in another clinical trial

          -  Prior history of eosinophilic pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miquel Pujol, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>(Infectious Diseases Service) Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar- Parc de Salut Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003 Jan 1;36(1):53-9. Epub 2002 Dec 13.</citation>
    <PMID>12491202</PMID>
  </reference>
  <reference>
    <citation>Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, O'Donnell A, Wagener MM, Yu VL. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003 Sep;82(5):333-9.</citation>
    <PMID>14530782</PMID>
  </reference>
  <reference>
    <citation>Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653-65.</citation>
    <PMID>16914701</PMID>
  </reference>
  <reference>
    <citation>Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, Corey GR, Abrutyn E. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008 Dec;62(6):1413-21. doi: 10.1093/jac/dkn372. Epub 2008 Sep 8.</citation>
    <PMID>18782781</PMID>
  </reference>
  <reference>
    <citation>Gudiol F, Aguado JM, Pascual A, Pujol M, Almirante B, Miró JM, Cercenado E, Domínguez Mde L, Soriano A, Rodríguez-Baño J, Vallés J, Palomar M, Tornos P, Bouza E; Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. [Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica]. Enferm Infecc Microbiol Clin. 2009 Feb;27(2):105-15. doi: 10.1016/j.eimc.2008.09.003. Epub 2009 Feb 11. Review. Spanish.</citation>
    <PMID>19254641</PMID>
  </reference>
  <reference>
    <citation>Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):127-42. doi: 10.1007/s10096-009-0833-2. Epub 2009 Nov 14. Review.</citation>
    <PMID>19915879</PMID>
  </reference>
  <reference>
    <citation>Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010 Apr;66(4):359-68. doi: 10.1007/s00228-010-0794-5. Epub 2010 Feb 26.</citation>
    <PMID>20186407</PMID>
  </reference>
  <reference>
    <citation>Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 1;52(3):285-92. doi: 10.1093/cid/cir034.</citation>
    <PMID>21217178</PMID>
  </reference>
  <reference>
    <citation>Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents. 2011 Sep;38(3):192-6. doi: 10.1016/j.ijantimicag.2011.03.006. Epub 2011 May 6. Review.</citation>
    <PMID>21549573</PMID>
  </reference>
  <reference>
    <citation>Chen LY, Huang CH, Kuo SC, Hsiao CY, Lin ML, Wang FD, Fung CP. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis. 2011 May 26;11:152. doi: 10.1186/1471-2334-11-152.</citation>
    <PMID>21612672</PMID>
  </reference>
  <reference>
    <citation>Miró JM, Entenza JM, Del Río A, Velasco M, Castañeda X, Garcia de la Mària C, Giddey M, Armero Y, Pericàs JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A; Hospital Clinic Experimental Endocarditis Study Group. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012 Aug;56(8):4511-5. Epub 2012 May 29.</citation>
    <PMID>22644033</PMID>
  </reference>
  <reference>
    <citation>Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011 Jun;31(6):527-36. doi: 10.1592/phco.31.6.527.</citation>
    <PMID>21923436</PMID>
  </reference>
  <reference>
    <citation>Gasch O, Ayats J, Angeles Dominguez M, Tubau F, Liñares J, Peña C, Grau I, Pallarés R, Gudiol F, Ariza J, Pujol M. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore). 2011 Sep;90(5):319-27. doi: 10.1097/MD.0b013e31822f0b54.</citation>
    <PMID>21862935</PMID>
  </reference>
  <reference>
    <citation>Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Molina J, Lopez-Medrano F, Ruiz E, Martinez JA, Bereciartua E, Rodriguez-Lopez F, Fernandez-Mazarrasa C, Goenaga MA, Benito N, Rodriguez-Baño J, Espejo E, Pujol M; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2013 Nov;19(11):1049-57. doi: 10.1111/1469-0691.12108. Epub 2013 Jan 17.</citation>
    <PMID>23331461</PMID>
  </reference>
  <reference>
    <citation>Garrigós C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Jan;57(1):606-10. doi: 10.1128/AAC.01570-12. Epub 2012 Oct 22.</citation>
    <PMID>23089756</PMID>
  </reference>
  <reference>
    <citation>Lai CC, Sheng WH, Wang JT, Cheng A, Chuang YC, Chen YC, Chang SC. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis. 2013 Feb 4;13:66. doi: 10.1186/1471-2334-13-66.</citation>
    <PMID>23379510</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Network for Research in Infectious Diseases</investigator_affiliation>
    <investigator_full_name>Miquel Pujol</investigator_full_name>
    <investigator_title>MD and PhD</investigator_title>
  </responsible_party>
  <keyword>MRSA</keyword>
  <keyword>bacteremia</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

